Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation develops high-performance scientific instruments and analytical and diagnostic solutions for life science, applied, biopharma, microscopy, nanoanalysis, industrial, cleantech and semiconductor metrology markets.
Recurring news for BRKR includes earnings updates for Bruker Scientific Instruments and Bruker Energy & Supercon Technologies, product launches across NMR, microbiology, infection diagnostics, spatial biology and AFM-IR spectroscopy, and governance changes. Company announcements also cover platforms such as MALDI Biotyper, IR Biotyper, MyGenius PRO, GeoMx, CellScape, CosMx and Dimension IconIR.
Bruker (Nasdaq: BRKR) announced accelerated development of its photothermal AFM-IR spectroscopy and installation of a Dimension IconIR system at imec on April 7, 2026. The initiative expands AFM-IR use beyond contamination analysis into EUV photoresist, transistor scaling materials, and nanoscale surface functionalization.
The collaboration is a Joint Development Project with imec to evaluate nanoscale chemical characterization, citing label-free chemical analysis with sub-5-nanometer resolution to support advanced semiconductor research.
Bruker (Nasdaq: BRKR) appointed Thierry L. Bernard to its Board of Directors effective April 1, 2026. Mr. Bernard is an experienced life‑science tools and diagnostics executive and current CEO of QIAGEN, who has led molecular diagnostics since 2015 and became CEO in 2019.
The company said he will support Bruker’s strategy across life‑science research, biopharma and diagnostics as it pursues profitable growth and margin expansion.
PreOmics and Biognosys (BRKR) announced a favorable PTAB decision: the U.S. Patent Trial and Appeal Board revoked central claims of U.S. Patent No. 11,435,360 (IPR2024-01473), including the sole independent Claim 1.
The patent is owned by The Brigham and Women’s Hospital and exclusively licensed to Seer; the revoked claim covered workflows using multiple nanoparticle types to form biomolecule coronas to detect proteins.
Bruker (Nasdaq: BRKR) launched CellScape XR, a next-generation spatial proteomics platform designed for diagnostic and prognostic assay development. The platform emphasizes quantitative performance, robustness, and high throughput, incorporating advances in optics, fluidics, and protocols to support translational and clinical studies.
Bruker cites collaborations at University Hospital Schleswig-Holstein, Kiel, where teams analyzed >1,000 clinically annotated samples and plan to expand to ~3,000 patient samples, illustrating CellScape XR's intended scalability for large clinical cohorts.
Bruker (Nasdaq: BRKR) is expanding its collaboration with Noetik to scale tissue foundational models using CosMx® Spatial Molecular Imager. The partnership follows a study of >3,500 patient samples and will add thousands more, aiming to train models on up to one billion spatially resolved human cells.
The work targets genome-wide, single-cell and subcellular spatial transcriptomic and multiomic datasets to support translational and therapeutic applications.
Bruker (Nasdaq: BRKR) unveiled major spatial biology product launches and platform upgrades at AGBT 2026, including PaintScape (3D genome visualization), CellScape XR (next‑gen spatial proteomics), CosMx mouse whole transcriptome, expanded GeoMx multiomics, and AtoMx AI‑ready analytics.
Commercial shipments: PaintScape this spring; CellScape XR shipments expected this summer; CosMx mouse WTX early access this spring and full availability later in 2026.
Bruker (Nasdaq: BRKR) announced upgrades to its timsOmni mass spectrometer and ProteoScape, OmniScape, and GlycoScape software on February 23, 2026 to advance "Functional Proteomics 2.0." New features include eXd-enabled glycoproteomics, the OmniWave algorithm for top-down proteoform identification, and AI-enhanced de novo peptide sequencing trained on >7 million spectra for database-independent discovery.
These updates target deeper proteoform and PTM characterization across disease research, immunopeptidomics, metaproteomics, and biotherapeutics analysis.
Bruker (Nasdaq: BRKR) reported Q4-25 revenue of $977.2M (flat yoy; -5.1% organic) and FY25 revenue of $3.44B (+2.1% reported; -3.7% organic). FY25 GAAP loss per share was $(0.15); non-GAAP EPS was $1.83. Bruker guided FY26 revenue to $3.57–3.60B and non-GAAP EPS to $2.10–2.15, noting an ~8% FX headwind to EPS and planned cost savings to expand margins.
Bruker (NYSE:BRKR) launched iNTApharma, a label-free, native-state nanoparticle characterization platform with single-particle sensitivity for viral vectors, LNPs, lentiviral vectors, and extracellular vesicles.
Optimized for particles 50–300 nm, it provides rapid size and concentration measurements, automated well‑plate acquisition, and will be placed with early-access partners in H1 2026 with broader commercial availability in H2 2026.
Chemspeed and SciY (Nasdaq: BRKR) unveiled an open Self‑Driving Lab (SDL) platform on February 9, 2026 at SLAS2026 to unify lab automation, analytics and AI orchestration.
The SDL offers vendor‑agnostic integration of modular precision automation, NMR/IR/MS/X‑ray analytics, and an AI‑ready FAIR data backbone to enable autonomous, 24/7 DMTA workflows and scalable QC/R&D operations.